Influence of healthy candidate bias in assessing clinical effectiveness for implantable cardioverter-defibrillators: Cohort study of older patients with heart failure open access

BMJ (Online)

Volumn 348, Issue , 2014, Pages

  Setoguchi, Soko ^a,b   Stevenson, Lynne Warner ^a   Stewart, Garrick C ^a   Bhatt, Deepak L ^a   Epstein, Andrew E ^c   Desai, Manisha ^d   Williams, Lauren A ^a   Chen, Chih Ying ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE REGISTRY; FEMALE; HEALTH STATUS; HEART EJECTION FRACTION; HEART FAILURE; HIP FRACTURE; HOSPITAL ADMISSION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORTALITY; NURSING HOME; OBSERVATIONAL STUDY; PATIENT SELECTION; PRIMARY PREVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; COHORT STUDIES; COMORBIDITY; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HEALTH STATUS; HEART FAILURE; HIP FRACTURES; HUMANS; MALE; MEDICARE; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; SELECTION BIAS; SKILLED NURSING FACILITIES; UNITED STATES;

EID: 84900423293     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g2866     Document Type: Article

References (44)

1. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37. (Pubitemid 40110811)
2. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83. (Pubitemid 34984635)
3. Centers for Medicare and Medicaid Services. National Coverage Determination (NCD) for Implantable Automatic Defibrillators (20.4). 2013. www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId= 110&ncdver=3.
4. Tung P, Albert CM. Causes and prevention of sudden cardiac death in the elderly. Nat Rev Cardiol 2013;10:135-42.
5. Mehta PA, Dubrey SW, McIntyre HF, Walker DM, Hardman SM, Sutton GC, et al. Mode of death in patients with newly diagnosed heart failure in the general population. Eur J Heart Fail 2008;10:1108-16.
6. Setoguchi S, Nohria A, Rassen JA, Stevenson LW, Schneeweiss S. Maximum potential benefit of implantable defibrillators in preventing sudden death after hospital admission because of heart failure. CMAJ 2009;180:611-6.
7. Fonarow GC, Yancy CW, Hernandez AF, Peterson ED, Spertus JA, Heidenreich PA. Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. Am Heart J 2011;161:1024-30. e3.
8. Setoguchi S, Zhu Y, Jalbert JJ, Williams LA, Chen CY. Validity of deterministic record linkage using multiple indirect personal identifiers: linking a large registry to claims data. Circ Cardiovasc Qual Outcomes 2014; published online 22 Apr.
9. Ray WA, Griffin MR, Fought RL, Adams ML. Identification of fractures from computerized medicare files. J Clin Epidemiol 1992;45:703-14.
10. Little RJ, Rubin DB. Statistical analysis with missing data. John Wiley, 2002.
11. Knol MJ, Janssen KJ, Donders AR, Egberts AC, Heerdink ER, Grobbee DE, et al. Unpredictable bias when using the missing indicator method or complete case analysis for missing confounder values: an empirical example. J Clin Epidemiol 2010;63:728-36.
12. Li CY, Sung FC. A review of the healthy worker effect in occupational epidemiology. Occup Med (Lond) 1999;49:225-9.
13. Hemminki E, Malin M, Topo P. Selection to postmenopausal therapy by women's characteristics. J Clin Epidemiol 1993;46:211-9. (Pubitemid 23107068)
14. Humphrey LL, Chan B K S, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med 2002;137:273-84.
15. Glynn RJ, Schneeweiss S, Wang PS, Levin R, Avorn J. Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. J Clin Epidemiol 2006;59:819-28. (Pubitemid 44040877)
16. Ray WA, Daugherty JR, Griffin MR. Lipid-lowering agents and the risk of hip fracture in a medicaid population. Inj Prev 2002;8:276-9.
17. Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol 2006;35:337-44.
18. Hallstrom AP, Greene HL, Huther ML. The healthy responder phenomenon in non-randomized clinical trials. Stat Med 1991;10:1621-31.
19. Cacciatore F, Abete P, Mazzella F, Viati L, Della Morte D, D'Ambrosio D, et al. Frailty predicts long-term mortality in elderly subjects with chronic heart failure. Eur J Clin Invest 2005;35:723-30. (Pubitemid 41783588)
20. Frasure-Smith N, Lesperance F, Habra M, Talajic M, Khairy P, Dorian P, et al. Elevated depression symptoms predict long-term cardiovascular mortality in patients with atrial fibrillation and heart failure. Circulation 2009;120:134-40, 3p following 140.
21. Friedmann E, Thomas SA, Liu F, Morton PG, Chapa D, Gottlieb SS. Relationship of depression, anxiety, and social isolation to chronic heart failure outpatient mortality. Am Heart J 2006;152:940.e1-8.
22. Konstam V, Salem D, Pouleur H, Kostis J, Gorkin L, Shumaker S, et al. Baseline quality of life as a predictor of mortality and hospitalization in 5, 025 patients with congestive heart failure. SOLVD Investigations. Studies of Left Ventricular Dysfunction Investigators. Am J Cardiol 1996;78:890-5. (Pubitemid 126658649)
23. Murberg TA. Long-term effect of social relationships on mortality in patients with congestive heart failure. Int J Psychiatry Med 2004;34:207-17. (Pubitemid 40128365)
24. Stevenson LW, Hellkamp AS, Leier CV, Sopko G, Koelling T, Warnica JW, et al. Changing preferences for survival after hospitalization with advanced heart failure. J Am Coll Cardiol 2008;52:1702-8.
25. Stewart GC, Weintraub JR, Pratibhu PP, Semigran MJ, Camuso JM, Brooks K, et al. Patient expectations from implantable defibrillators to prevent death in heart failure. J Card Fail 2010;16:106-13.
26. Lee DS, Tu JV, Austin PC, Dorian P, Yee R, Chong A, et al. Effect of cardiac and noncardiac conditions on survival after defibrillator implantation. J Am Coll Cardiol 2007;49:2408-15. (Pubitemid 46962260)
27. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines Maryland, andat the 2013 scientific meeting for the American Heart Association, November 18, 2013, in Dallas, Texas. Contributors: SS and LWS contributed to the acquisition of the data. SS and LWS developed the study design. SS, CYC, and MD contributed to the analysis of the data. SS and CYC drafted the manuscript. All authors contributed to the interpretation of the data and the revision of the work, and all approved the final version to be published. SS is guarantor. The authors of this report are responsible for its content. Statements in the report should not be construed as endorsement by the Agency for Healthcare Research and Quality or the US Department of Health and Human Services. Funding: This project was funded under contract No HHSA 29020050016I, task order 3, from the Agency for Healthcare Research and Quality, US Department of Health and Human Services, as part of the Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) program; and contract No HHSM 500201000001I, task orders 2 and 6, from the Centers for Medicare and Medicaid Services, US Department of Health and Human Services. SS was supported by midcareer development award K02HS 017731 from the Agency for Healthcare Research and Quality. Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi-disclosure.pdf (available on request from the corresponding author). SS reported receiving grants from Agency for Healthcare Research and Quality and from the Center for Medicare and Medicaid Services during the conduct of the study. She has made available online a detailed listing of financial disclosures (www.dcri.duke.edu/about-us/conflict- of-interest/). DLB reported receiving grants from Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Medtronic, Roche, Sanofi Aventis, and The Medicines Company; conducting unfunded research for FlowCo, PLx Pharma, and Takeda; receiving personal fees from the Duke Clinical Research Institute, the Mayo Clinic, the Population Health Research Institute, the American College of Cardiology, Belvoir Publications, Slack Publications, WebMD, and Elsevier Practice Update Cardiology; serving on advisory boards for Elsevier Practice Update Cardiology, Medscape Cardiology, and Regado Biosciences; serving on the board of directors of the Boston VA Research Institute and the Society of Cardiovascular Patient Care; receiving non-financial support from the Society of Cardiovascular Patient Care and the American Heart Association; and serving as editor for the Journal of Invasive Cardiology, outside of the submitted work. AEE reported receiving honorariums from Biotronik, Boston Scientific, Medtronic, and St Jude Medical; receiving research funding from Biotronik, Boston Scientific, Medtronic, and St Jude Medical; and receiving fellowship program support from Biotronik, Boston Scientific, Medtronic, and St Jude Medical. Ethical approval: This study was approved by the institutional review board of Brigham and Women's Hospital. Data sharing: No additional data available. Transparency: The lead author affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any for the Evaluation and Management of Heart Failure): developed in collaboration with th American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112:e154-e235
28. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 o the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC. Eur Heart J 2012;33:1787-847.
29. Epstein AE, Dimarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS, et al ACC/AHA/HRS 2008 guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: executive summary. Heart Rhythm 2008;5:934-55.
30. Hernandez AF, Fonarow GC, Liang L, Al-Khatib SM, Curtis LH, La Bresh KA, et al. Sex and racial differences in the use of implantable cardioverter- defibrillators among patient hospitalized with heart failure. JAMA 2007;298:1525-32. (Pubitemid 47529386)
31. Piccini JP, Hernandez AF, Dai D, Thomas KL, Lewis WR, Yancy CW, et al. Use of cardia resynchronization therapy in patients hospitalized with heart failure. Circulation 2008;118:926-33.
32. Bavry AA, Bhatt DL. Interpreting observational studies-look before you leap. J Clin Epidemiol 2006;59:763-4. (Pubitemid 43975733)
33. Salas M, Hotman A, Stricker BH. Confounding by indication: An example of variation in the use of epidemiologic terminology. Am J Epidemiol 1999;149:981-3. (Pubitemid 29246861)
34. Chan PS, Chow T, Kereiakes D, Schloss EJ, Waller T, Eagle K, et al. Effectiveness of implantable cardioverter-defibrillators in patients with ischemic heart disease and left ventricular dysfunction. Arch Intern Med 2006;166:2228-33. (Pubitemid 44753827)
35. Hernandez AF, Fonarow GC, Hammill BG, Al-Khatib SM, Yancy CW, O'Connor CM, et al. Clinical effectiveness of implantable cardioverter-defibrillators among Medicare beneficiaries with heart failure. Circ Heart Fail 2010:3;7-13.
36. Fox AC, Collier PF. Low mortality rates in industrial cohort studies due to selection for work and survival in the industry. Br J Prev Soc Med 1976;20:225-30. (Pubitemid 8017332)
37. Checkoway H, Pearce N, Hickey JL, Dement JM. Latency analysis in occupational epidemiology. Arch Environ Health 1990;45:95-100.
38. Robins J. A new approach to causal inference in mortality studies with a sustained exposure period: Application to control of the healthy worker survivor effect. Math Modeling 1986;7:1393-512.
39. Robins J. The control of confounding by intermediate variables. Stat Med 1989;8:679-701. (Pubitemid 19179868)
40. Setoguchi S, Glynn RJ, Avorn J, Mogun H, Schneeweiss S. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation 2007;115:27-33. (Pubitemid 46058608)
41. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009;20:512-22.
42. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004;351:2481-8. (Pubitemid 39603155)
43. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-12.
44. Skali H, Uno H, Levey AS, Inker LA, Pfeffer MA, Solomon SD. Prognostic assessment of estimated glomerular filtration rate by the new chronic kidney disease epidemiology collaboration equation in comparison with the modification of diet in renal disease study equation. Am Heart J 2011;162:548-54.